Abstract
Arecoline hydrobromide has been used for almost half a century for the treatment of Echinococcus granulosus in dogs. Trials in New Zealand showed that it had real limitations for this purpose. Its main value lies in its use as a diagnostic agent for detecting infections in dogs on a group basis. The data so obtained can be used in educating dog owners as well as for providing base-line data and an index of progress in a continuing control programme. The drug's limitations for treatment and value as a diagnostic agent in a field trial are assessed.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Borrie J., Gemmell M. A., Manktelow B. W. An experimental approach to evaluate the potential risk of hydatid disease from inhalation of echinococcus ova. Br J Surg. 1965 Nov;52(11):876–878. doi: 10.1002/bjs.1800521110. [DOI] [PubMed] [Google Scholar]
- FORBES L. S. THE RELATION BETWEEN METHOD OF ADMINISTRATION, ROUTE OF ABSORPTION, INHIBITORY ACTIONS AND ACUTE TOXICITY OF ARECOLINE HYDROBROMIDE IN DOGS. Ann Trop Med Parasitol. 1964 Jun;58:119–131. doi: 10.1080/00034983.1964.11686222. [DOI] [PubMed] [Google Scholar]
- FORBES L. S. THE USE OF ARECOLINE HYDROBROMIDE IN THE TREATMENT OF TAENIID INFECTIONS IN DOGS. Ann Trop Med Parasitol. 1964 Mar;58:116–118. doi: 10.1080/00034983.1964.11686221. [DOI] [PubMed] [Google Scholar]
- GEMMELL M. A. Cestode problems of domestic animals and man in the South Island of New Zealand. N Z Med J. 1958 Oct;57(321):442–458. [PubMed] [Google Scholar]